Maddalena Opioid Switching Score in patients with cancer pain.
Journal
Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
received:
13
12
2021
accepted:
20
04
2022
pubmed:
3
5
2022
medline:
23
12
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Evaluation of opioid switching (OS) for cancer pain has not been properly assessed. The aim of this study was to assess an integrated score (Maddalena Opioid Switching Score) as a simple and repeatable tool to evaluate the outcomes of OS, facilitating the interpretation and comparison of studies, and information exchange among researchers. The integrated score took into account pain intensity, intensity of opioid-related symptoms, and cognitive function by using an author's formula. Physical and psychological symptoms were evaluated by the Edmonton Symptom Assessment Scale and Patient Global Impression (PGI) by the minimal clinically important difference. One hundred six patients were analyzed. Ninety-five patients were switched successfully, and 11 patients underwent a further OS and/or an alternative procedure. The Maddalena Opioid Switching Score significantly decreased after OS and was highly correlated to PGI of improvement ( P < 0.0005). In patients with unsuccessful OS, no significant changes in the Maddalena Opioid Switching Score and PGI were observed. A significant reduction in Edmonton Symptom Assessment Scale items intensity was observed after OS. The Maddalena Opioid Switching Score resulted to be a sensitive instrument for measuring the clinical improvement produced by OS.
Identifiants
pubmed: 35500284
doi: 10.1097/j.pain.0000000000002669
pii: 00006396-202301000-00015
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-97Informations de copyright
Copyright © 2022 International Association for the Study of Pain.
Références
Bedart G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M, Danjoux C, Barnes E, Sahgal A, Poon M, Chow E. Minimal clinically important differences in the Edmonton Symptom Assessment System in patients with advanced cancer. J Pain Symptom Manage 2013;46:192–200.
Bouassirha D, Attal N, Alchaar H, Boureau F, Brochet B, Btuxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lanteri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). PAIN 2005;114:29–36.
Breibart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delrium Assessment Scale. J Pain Symptom Manage 1997;13:128–37.
de la Cruz M, Yennu S, Liu D, Wu J, Reddy A, Bruera E. Increased symptom expression among patients with delirium admitted to an acute palliative care unit. J Palliat Med 2017;20:638–41.
Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003;25:406–11.
Gonzales-Barboteo J, Gomez-Batiste X, Calvo M, Alberola Candel V, Palacios Eito MA, Sanchez-Magro I, Alvarez MN, Perez Martin FJ, Porta-Sales J. Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL Study. J Opioid Manage 2014;10:395–403.
Hui D, Park M, Shamieh O, Paiva CE, Perez-Cruz PE, Muckaden MA, Bruera E. Personalized symptom goals and response in patients with advanced cancer. Cancer 2016;122:1774–81.
Dalal S, Hui D, Nguyen L, Chacko R, Scott C, Roberts L, Bruera E. Achievement of personalized pain goal in cancer patients referred to a supportive care clinic at a comprehensive cancer center. Cancer 2012;118:3869–77.
Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. J Pain Symptom Manage 2017;53:630–43.
Kloke M, Rapp M, Bosse B, Kloke O. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 2000;8:479–86.
Knudsen AK, Brunelli C, Klepstad P, Aas N, Apolone G, Corli O, Montanari M, Caraceni A, Kaasa S. Which domains should be included in a cancer pain classification system? Pain. 2012;153:696–703.
Lauridsen HH, Hartvigsen J, Manniche C, Korsholm L, Grunnet-Nilsson N. Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients. BMC Musculoskelet Disord 2006;7:82.
Legakis LP, Woo W, Cassel JB, Del Fabbro E. Comparison of opioid rotation on pain, symptoms, and daily opioid dose in a supportive care clinic. Ann Palliat Med 2021;10:6336–43.
McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231–56.
Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001;21:144–50.
Mercadante S, Ferrera P, Villari P, casuccio A, Intravaia G, Mangione S. Frequency, indications, outcomes, and predictive factors pf opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632–41.
Mercadante S. Stop and go strategy for opioid switching requires flexibility. Eur J Cancer 2012;48:944–7.
Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol 2016;99:241–8.
Mercadante S, Caruselli A, Casuccio A. The use of ketamine in a palliative-supportive care unit: a retrospective analysis. Ann Palliat Med 2018;7:205–10.
Mercadante S, Adile C, Lanzetta G, Mystakidou K, Maltoni M, Guilherme Soares L, De Santis S, Ferrera P, Valenti M, Rosati M, Rossi R, Cortegiani A, Masedu F, Marinangeli F, Aielli F. Personalized symptom goals and patient global impression on clinical changes in advanced cancer patients. Oncologist 2019;24:239–46.
Mercadante S. The patient with difficult pain. Cancers (Basel) 2019;11:565.
Mercadante S, Adile C, Ferrera P, Cortegiani A, Casuccio A. Symptom expression in patients with advanced cancer admitted to an acute supportive/palliative care unit with and without delirium. Oncologist 2019;24:e358–64.
Mercadante S. Opioid analgesics adverse effects: the other side of the coin. Curr Pharm Des 2019;25:3197–202.
Mercadante S, Coluzzi F. Factors influencing pain expression in patients with cancer: an expert opinion. Pain Ther 2021;10:765–75.
Mulvey MR, Boland EG, Bouhassira D, Freynhagen R, Hardy J, Hjermstad MJ, Mercadante S, Pérez C, Bennett MI. Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. Br J Anaesth 2017;119:765–74.
Oian Y, Haider A, Lu Z, Naqvi S, Zhuang A, Nguyen K, Reddy A, Arthur J, Tanco K, Williams J, Wu J, Liu D, Naberhuis J, Bruera E. Factors associated with improvement in uncontrolled cancer pain without increasing the opioid daily dose among patients seen by an inpatient palliative care team. J Palliat Med 2020;23:483–88.
Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695–700.
Reddy A, Yennurajalingam S, Pulivarthi K, Palla SL, Wang X, Kwon JH, Frisbee-Hume S, Bruera E. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 2013;18:212–20.
Reddy A, Yennurajalingam S, de la Cruz M, Palla SL, Wang X, Kwon JH, Frisbee-Hume S, Bruera E. Factors associated with survival after opioid rotation in cancer patients presenting to an outpatient supportive care center. J Pain Symptom Manage 2014;48:92–8.
Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 2006;11:765–73.
Smith MA, Quirk KC, Saul DC, Rodgers PE, Silveira MJ. Comparing methadone rotation to consensus opinion. J Pain Symptom Manage 2020;59:116–20.